Program
BAT3306
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Bio-Thera Solutions.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bio-Thera Solutions | 21 open or running | phase 3since Feb 4, 2024 | Feb 4, 2024 | Feb 28, 2027phase 1 · NCT07180862 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 4, 2024First study: phase 3 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06280196 · 162 enrolled · China
- Aug 19, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07180862 · 160 enrolled · China
Ahead
- Feb 28, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07180862
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07180862Carcinoma, Non-Small-Cell Lung · China | 1 | Active, not recruiting | Feb 28, 2027 | 160 |
| NCT06280196Carcinoma, Non-Small-Cell Lung · China | 3 | Terminated | Jul 30, 2025 | 162 |
How it is read
Names in the registry
- “BAT3306”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.